Nov 20, 2020 / 04:00PM GMT
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the tirzepatide SURPASS program overview. (Operator Instructions) As a reminder, today's call is being recorded.
Now I'll turn the conference over to your host, Kevin Hern. Please go ahead.
Kevin Hern - Eli Lilly and Company - VP of IR
Good morning. Thank you for joining us for Eli Lilly and Company's overview of the tirzepatide SURPASS Phase III program. I'm Kevin Hern, Vice President of Investor Relations. Joining me on today's call are Mike Mason, President of Lilly Diabetes; Dr. Dan Skovronsky, Chief Scientific Officer; Dr. Jeff Emmick, Vice President of Diabetes Global Product Development; and Jamie Croaning, Global Development Leader for tirzepatide.
During this conference call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to a number of factors, including those listed on Slide 3 and those outlined in our latest forms 10-K, 10-Q and 8-K filed with the Securities and Exchange
Eli Lilly and Co to Provide an Overview of Tirzepatide Phase 3 Clinical Program - Conference Call Transcript
Nov 20, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers